Our focus

Our Mission

Aurum Ventures MKI provides value added growth capital to exceptional entrepreneurs within the fields of life-sciences and clean-tech. While we focus on investing in unique, cutting edge technologies that will mature into successful business companies, our investments reflect our own values, so we prefer investing in companies that, through their sound commercial propositions, also contribute to the well-being of mankind. Our team is comprised of senior and experienced hands-on executives who work actively with the portfolio companies in enhancing their strategic and execution capabilities. We typically take a long-term approach, understanding that ventures in the life sciences and clean tech take time to mature and be successful.

Strategy

Aurum Ventures provides financing and other managerial resources to life science companies in all stages of development. Aurum Ventures’ focus is almost solely upon novel therapeutics, whether devices or pharmaceuticals, but from time to time we will also consider non-therapeutics such as agricultural biotechnology or bio energy. Aurum is continually entering into novel ventures and has a strong track record of partnering with portfolio companies to ensure timely clinical trials as required in most life science companies. Aurum will invest either alone or co- invest with other reliable partners either in a lead or follower position. Aurum will invest in both early and late stage projects, but our geographical focus is upon Israeli and Israel related opportunities.

About US

Life Sciences

Aurum Ventures MKI is the technology investment arm of Morris Kahn, a prominent business man, philanthropist and entrepreneur. Morris Kahn is one of the founders of the Aurec Group, which has become a leading provider in the communication, media and information fields in Israel and around the world.

Portfolio

  • PolyPid

    polypid

    PolyPid is a clinical stage specialty pharmaceutical company engaged focusing on targeted, localized drug delivery into the body over periods of time ranging from days to several months.

    polypid
    PolyPid
  • Beta-O2

    beta-o2

    Beta-O2 develops a bio-artificial pancreas for the cure of Type-1 Diabetes (T1D). The device is an implantable device containing insulin secreting cells.

    beta-o2
    Beta-O2
  • VBL Therapeutics Ltd

    vblrx

    VBL is a clinical stage biopharmaceutical company committed to the development of a novel anti-cancer approach. VBL is publically traded at NASDAQ under the ticker symbol: VBLT.

    vblrx
    VBL Therapeutics Ltd
  • LifeBond

    lifebond

    LifeBond is a clinical stage company developing a line of biosurgical products for the prevention of post-surgical leakages and bleedings.

    lifebond
    LifeBond
Go Back

Our Team

Ms. Hava Bar Shay
Ms. Hava Bar Shay
Chief Executive Officer, Aurum Group
Prior to joining Aurum in 2015, Hava was an executive in leading organizations. Hava held numerous professional positions mainly in Human resources in Maccabi Healthcare services, Amdocs and in the Flying Cargo group. From 2008 to 2011 Hava was the managing director at FEDEX Domestic Israel. She is on the board of public organizations in the Public Health and Municipal Utilities areas. Hava holds a B.A. in Education and International relationship from the Hebrew University and a M.Sc. in Healthcare Management from Ben-Gurion University.
Dr. Dan Gelvan
Dr. Dan Gelvan
Managing Director of Life Sciences
Dr. Dan Gelvan is a seasoned life-science executive who before joining Aurum Ventures managed GammaCan International, Inc., a development-stage pharmaceutical company. Previously, Dr Gelvan founded and managed Zetiq Technologies, a drug discovery company specializing in cell-based high-throughput screening for novel anti-cancer drugs. Dr Gelvan founded Zetiq after leaving a senior position in Clal (Israel) Ltd., one of Israel’s largest holding conglomerates. Dr Gelvan holds a PhD in Business Economics from RUC in Denmark, and a BA and MA in Economics from the Hebrew University in Jerusalem. Dan is an experienced lecturer of corporate finance and entrepreneurship. Dr Gelvan was a member of Israel’s National Committee for Biotechnology for an extended period of time.
Nir Dror
Nir Dror
CFO
Nir Dror joined Aurum Ventures in 2013. Nir brings with him over 10 years of experience in finance, including investment banking and private equity experience. Nir is actively involved in due diligence, value assessment, financial engineering, transactions and M&A activities. Nir works closely with the portfolio companies on all financial issues. Prior to joining Aurum, Nir served as the Chief Investment Officer at Origo Investments, a $350mm investment fund. Previously, Nir worked as an associate at Barclays Capital (formerly Lehman Brothers) where he was responsible for global transactions such as M&As, debt restructuring, and IPOs. Nir holds a Bachelor degree in Law and Accounting from Tel Aviv University, Master degree in Commercial Law from Tel Aviv University and an MBA (cum laude) from the Michigan Ross School of Business.
Ilan Lior
Ilan Lior
General Counsel
Ilan Lior joined Aurum in 2014. He handles all legal matters relating to the Aurum group of companies, the various investment transactions and supports the portfolio companies on various legal issues. Prior to joining Aurum, Ilan was a partner in a boutique law firm where he headed the corporate and commercial practice group and advised clients on issues such as corporate financing and restructurings, joint ventures and M&A activities. He also worked extensively on matters of licensing agreements, purchase agreements and arrangements relating to intellectual property. In his work, Ilan has specialized in cross-border cases and represented a wide range of clients ranging from start-ups and other privately held companies, public enterprises, municipal bodies and governmental agencies, with special expertise in international infrastructure tenders. Ilan is a member of the Israel Bar Association since 1998. As a graduate of Tel Aviv University joint bachelor program in Law and Economics, he also holds a B.A. in Economics.

Contact Us